- Home
- RS vs VTRS Comparison
RS vs VTRS Comparison
Compare RS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RS | VTRS |
|---|---|---|
| Founded | 1939 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 17.2B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RS | VTRS |
|---|---|---|
| Price | $308.93 | $14.55 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 6 |
| Target Price | ★ $324.33 | $11.83 |
| AVG Volume (30 Days) | 375.3K | ★ 10.3M |
| Earning Date | 05-21-2026 | 05-27-2026 |
| Dividend Yield | 1.60% | ★ 3.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 13.98 | N/A |
| Revenue | ★ $14,805,900,000.00 | $14,299,900,000.00 |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $1.03 | $1.60 |
| P/E Ratio | $22.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $250.07 | $6.85 |
| 52 Week High | $365.59 | $16.47 |
Technical Indicators
Market Signals| Indicator | RS | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 45.57 |
| Support Level | $283.39 | $9.82 |
| Resistance Level | $315.08 | $16.38 |
| Average True Range (ATR) | 11.48 | 0.49 |
| MACD | -3.49 | -0.26 |
| Stochastic Oscillator | 10.68 | 4.61 |
Price Performance
Historical ComparisonAbout RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.